Cellular delivery and retention of photofrin: II. The effects of human versus mouse and bovine serum.
The effects of human serum (HS), mouse serum (MS) and fetal bovine serum (FBS) on cellular delivery and retention of Photofrin were examined using human lung tumor cells (A549) cultured in vitro. The results show that these three kinds of sera exhibit substantial differences in: (i) degree of inhibition of Photofrin cellular uptake, (ii) retention capacity of Photofrin delivered to the cells in their presence and (iii) efficacy of promoting the clearance of Photofrin from the cells. It is suggested that these differences originate from unequal interaction of each of the sera with Photofrin material, which in turn is the consequence of variability in composition and in the levels of serum proteins in HS, MS and FBS. The highest degree of Photofrin disaggregation and and competitive binding of its constituents was attributed to HS. The lowest degree of Photofrin disaggregation, and the competitive binding limited mostly to monomeric porphyrin forms was implicated for FBS. For MS, the spectroscopic and cellular data indicated a lesser degree of Photofrin disaggregation than with HS, with little if any consequence in Photofrin retention characteristics. The implication of this comparative analysis is that in vitro studies using FBS may underestimate the extent of interaction of Photofrin with serum proteins in humans, and overestimate the retention capacity of the photosensitizer in human tissues. Studies in vivo using a mouse model may also underestimate the degree of disaggregation of Photofrin in human circulation, and give different photosensitizer tissue retention levels than in humans.
Korbelik
M
M
Cancer Imaging, British Columbia Cancer Research Centre, Vancouver, Canada.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001692:Biological Transport; D001769:Blood; D001798:Blood Proteins / Q000032:analysis; D002417:Cattle; D004337:Drug Carriers; D017324:Hematoporphyrin Derivative / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008175:Lung Neoplasms; D051379:Mice; D011838:Radiation-Sensitizing Agents / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001798:Blood Proteins; D004337:Drug Carriers; D008055:Lipids; D008074:Lipoproteins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative